Is the consensus that the interim review by the DS
Post# of 148286
So, is the DSMB essentially irrelevant at this point? The data for 295 patients doesn't matter since we will have data for 390 patients at basically the same time?
The ball will primarily be in FDA's court, with no need for an opinion from the DSMB?